166 related articles for article (PubMed ID: 28849690)
1. Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
Hiemcke-Jiwa LS; Leguit RJ; Radersma-van Loon JH; Westerweel PE; Rood JJM; Doorduijn JK; Huibers MMH; Minnema MC
Leuk Lymphoma; 2018 May; 59(5):1256-1259. PubMed ID: 28849690
[No Abstract] [Full Text] [Related]
2. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
Cabannes-Hamy A; Lemal R; Goldwirt L; Poulain S; Amorim S; Pérignon R; Berger J; Brice P; De Kerviler E; Bay JO; Sauvageon H; Beldjord K; Mourah S; Tournilhac O; Thieblemont C
Am J Hematol; 2016 Mar; 91(3):E17-9. PubMed ID: 26689870
[No Abstract] [Full Text] [Related]
3. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
Hartsell L; Janes A; Larck C; Park S; Arnall JR
J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib therapy for lymphoplasmacytic lymphoma.
Helber MJ; Moore JE; Williams AM; Meacham PJ; Rothberg PG; Zent CS
Am J Hematol; 2017 Sep; 92(9):E542-E544. PubMed ID: 28543765
[No Abstract] [Full Text] [Related]
5. Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.
Plander M; Szendrei T; Vadvári Á; Iványi J
Pathol Oncol Res; 2020 Jan; 26(1):591-592. PubMed ID: 30357751
[No Abstract] [Full Text] [Related]
6.
Gustine JN; Xu L; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Keezer A; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ
Blood Adv; 2019 Oct; 3(19):2800-2803. PubMed ID: 31570491
[No Abstract] [Full Text] [Related]
7. Ibrutinib in pretreated Waldenström's macroglobulinaemia.
Bagcchi S
Lancet Oncol; 2015 May; 16(5):e204. PubMed ID: 25892147
[No Abstract] [Full Text] [Related]
8. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
Castillo JJ; Ghobrial IM; Treon SP
Leuk Lymphoma; 2016 Nov; 57(11):2699-701. PubMed ID: 26980069
[No Abstract] [Full Text] [Related]
9. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Yosef A; Touloukian EZ; Nambudiri VE
J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
[TBL] [Abstract][Full Text] [Related]
10. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
Vos JM; Tsakmaklis N; Patterson CJ; Meid K; Castillo JJ; Brodsky P; Ganz T; Pals ST; Kersten MJ; Xu L; Yang G; Treon SP; Hunter ZR
Haematologica; 2017 Nov; 102(11):e452-e455. PubMed ID: 28798070
[No Abstract] [Full Text] [Related]
11. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
Castillo JJ; Gustine JN; Meid K; Dubeau T; Severns P; Treon SP
Haematologica; 2018 Jul; 103(7):e307-e310. PubMed ID: 29472352
[No Abstract] [Full Text] [Related]
12. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
13. Bing-Neel Syndrome Successfully Treated with Tirabrutinib.
Oyama T; Taoka K; Chiba A; Matsuda K; Maki H; Masamoto Y; Kurokawa M
Intern Med; 2022 Dec; 61(23):3575-3579. PubMed ID: 35569989
[TBL] [Abstract][Full Text] [Related]
14. Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
Tripathi A; Steingart R
J Oncol Pract; 2016 May; 12(5):490-1. PubMed ID: 27170696
[No Abstract] [Full Text] [Related]
15. Rare case of Bing-Neel syndrome treated successfully with ibrutinib.
Hashmi H; Dhanoa JS; Emmons R
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31243026
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib-induced acute liver failure.
Kahn A; Horsley-Silva JL; Lam-Himlin DM; Reeder CB; Douglas DD; Carey EJ
Leuk Lymphoma; 2018 Feb; 59(2):512-514. PubMed ID: 28693376
[No Abstract] [Full Text] [Related]
17. Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome.
Boudin L; Patient M; Roméo E; Bladé JS; de Jauréguiberry JP
Leuk Lymphoma; 2018 Nov; 59(11):2746-2748. PubMed ID: 29569974
[No Abstract] [Full Text] [Related]
18. Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Advani P; Paulus A; Ailawadhi S
Hematol Oncol Stem Cell Ther; 2019 Dec; 12(4):179-188. PubMed ID: 31158330
[TBL] [Abstract][Full Text] [Related]
19. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
Treon SP; Xu L; Hunter Z
N Engl J Med; 2015 Aug; 373(6):584-6. PubMed ID: 26244327
[No Abstract] [Full Text] [Related]
20. Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation.
Chan KL; Lokan J; Tam CS; Lew TE; Prince HM
Leuk Lymphoma; 2017 Jan; 58(1):207-210. PubMed ID: 27326828
[No Abstract] [Full Text] [Related]
[Next] [New Search]
